EP4581143A1 — Antisense oligonucleotide-based anti-fibrotic therapeutics
Assigned to University of Rochester · Expires 2025-07-09 · 1y expired
What this patent protects
The present application provides antisense oligonucleotides capable of enhancing expression of an anti-fibrosis gene or reducing expression of a pro-fibrosis gene in a target tissue. The antisense oligonucleotides may be used for the treatment of cardiac fibrosis. The antisense o…
USPTO Abstract
The present application provides antisense oligonucleotides capable of enhancing expression of an anti-fibrosis gene or reducing expression of a pro-fibrosis gene in a target tissue. The antisense oligonucleotides may be used for the treatment of cardiac fibrosis. The antisense oligonucleotide may include a gapmer capable of binding to, and forming a double- stranded structure with, a target sequence in a mRNA of a pro-fibrosis gene.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.